SCHEMBL24309393

SCHEMBL24309393

Cc1cccc(C)c1-c1cc(Oc2ccc(Cl)nc2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 2/20 0.36
▸ HTR7 P34969 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ CCNT1 O60563 1/20 0.34
▸ CCNB2 O95067 1/20 0.34
▸ CCNE2 O96020 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CCNB1 P14635 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ CCNB3 Q8WWL7 1/20 0.34
▸ MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566346 1.00 HTR1A (0.36) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL26810218 0.90 KMT2A (0.40) SMN1; SMN2TSHRMEN1KMT2AGPR119
SCHEMBL26814536 0.89 PIK3CD (0.36) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL26806497 0.88 PIK3CD (0.36) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL29566970 0.88 HRH3 (0.37) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL24309468 0.88 HRH3 (0.37) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL26810238 0.87 SMN1; SMN2 (0.38) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL29566612 0.87 TSHR (0.43) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL24310345 0.87 TSHR (0.43) HTR1AHTR7SMN1; SMN2TSHRPIK3CD
SCHEMBL24310086 0.86 GAA (0.40) HTR1AHTR7SMN1; SMN2TSHRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HTR1A 4018/4885HTR7 3833/4885SMN1; SMN2 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback